Her-2-neu expression and progression toward androgen independence in human prostate cancer.

BACKGROUND Human prostate cancers are initially androgen dependent but ultimately become androgen independent. Overexpression of the Her-2-neu receptor tyrosine kinase has been associated with the progression to androgen independence in prostate cancer cells. We examined the expression of Her-2-neu in normal and cancerous prostate tissues to assess its role in the progression to androgen independence. METHODS Prostate cancer tissue sections were obtained from 67 patients treated by surgery alone (UNT tumors), 34 patients treated with total androgen ablation therapy before surgery (TAA tumors), and 18 patients in whom total androgen ablation therapy failed and who developed bone metastases (androgen-independent [AI] disease). The sections were immunostained for Her-2-neu, androgen receptor (AR), prostate-specific antigen (PSA), and Ki-67 (a marker of cell proliferation) protein expression. Messenger RNA (mRNA) levels and gene amplification of Her-2-neu were examined by RNA in situ hybridization and fluorescent in situ hybridization(FISH), respectively, in a subset of 27 tumors (nine UNT, 11 TAA, and seven AI). All statistical tests were two-sided. RESULTS Her-2-neu protein expression was statistically significantly higher in TAA tumors than in UNT tumors with the use of two different scoring methods (P =.008 and P =.002). The proportion of Her-2-neu-positive tumors increased from the UNT group (17 of 67) to the TAA group (20 of 34) to the AI group (14 of 18) (P<.001). When compared with UNT tumors, tumor cell proliferation was higher in AI tumors (P =.014) and lower in TAA tumors (P<.001). All tumors expressed AR and PSA proteins. Although Her-2-neu mRNA expression was high in TAA and AI tumors, no Her-2-neu gene amplification was detected by FISH in any of the tumor types. CONCLUSIONS Her-2-neu expression appears to increase with progression to androgen independence. Thus, therapeutic targeting of this tyrosine kinase in prostate cancer may be warranted.

[1]  R Montironi,et al.  p63 is a prostate basal cell marker and is required for prostate development. , 2000, The American journal of pathology.

[2]  M. Loda,et al.  Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1 , 2000, Nature.

[3]  M. Hung,et al.  The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis , 2000, Nature Medicine.

[4]  C. Cordon-Cardo,et al.  Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. , 1999, Cancer research.

[5]  A. Belldegrun,et al.  Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. , 1999, Cancer research.

[6]  S. Schwartz,et al.  Prognostic value of immunohistochemical expression of the c‐erbB‐2 oncoprotein in metastasic prostate cancer , 1999, International journal of cancer.

[7]  D. Slamon,et al.  Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. , 1999, Seminars in oncology.

[8]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. T. Abreu-Martin,et al.  Mitogen-Activated Protein Kinase Kinase Kinase 1 Activates Androgen Receptor-Dependent Transcription and Apoptosis in Prostate Cancer , 1999, Molecular and Cellular Biology.

[10]  H. Mark,et al.  Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. , 1999 .

[11]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[12]  M. Sadar.  Androgen-independent Induction of Prostate-specific Antigen Gene Expression via Cross-talk between the Androgen Receptor and Protein Kinase A Signal Transduction Pathways* , 1999, The Journal of Biological Chemistry.

[13]  T. Visakorpi.  New pieces to the prostate cancer puzzle , 1999, Nature Medicine.

[14]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[15]  T C Gasser,et al.  Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.

[16]  S. Schwartz,et al.  Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis. , 1999, International journal of oncology.

[17]  H. Frierson,et al.  Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.

[18]  J. Kral,et al.  An Analysis of Microvessel Density, Androgen Receptor, p53 and HER-2/neu Expression and Gleason Score in Prostate Cancer , 1998, European Urology.

[19]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[20]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[21]  G. Wilding,et al.  Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Schwartz,et al.  Over‐expression of epidermal growth factor receptor and c‐ erbB2/neu but not of int‐2 genes in benign prostatic hyperplasia by means of semi‐quantitative PCR , 1998, International journal of cancer.

[23]  H. Klocker,et al.  Expression, structure, and function of androgen receptor in advanced prostatic carcinoma , 1998, The Prostate.

[24]  J. Ross,et al.  Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Wood,et al.  Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. , 1998, British Journal of Cancer.

[26]  R. Montironi,et al.  Pathological changes in prostate lesions after androgen manipulation. , 1998, Journal of clinical pathology.

[27]  M. Loda,et al.  Heterogeneity of androgen receptor content in advanced prostate cancer. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[28]  C. Sheehan,et al.  HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. , 1997, Human pathology.

[29]  J. Ross,et al.  Prognostic significance of HER‐2/neu gene amplification status by fluorescence in Situ hybridization of prostate carcinoma , 1997, Cancer.

[30]  J Isola,et al.  Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.

[31]  M. Melhem,et al.  Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. , 1997, The cancer journal from Scientific American.

[32]  L. Nazareth,et al.  Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.

[33]  K. Griffiths,et al.  Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis , 1996, The Prostate.

[34]  A. Mes-Masson,et al.  Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. , 1996, Cancer letters.

[35]  O. Lukkarinen,et al.  Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. , 1995, The Journal of clinical endocrinology and metabolism.

[36]  A. Bergh,et al.  Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. , 1995, The American journal of pathology.

[37]  D. Altman,et al.  Multiple significance tests: the Bonferroni method. , 1995, BMJ.

[38]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[39]  M. Colombel,et al.  Hormonal control of apoptosis: the rat prostate gland as a model system. , 1995, Methods in cell biology.

[40]  W. Grizzle,et al.  Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. , 1994, Journal of the National Cancer Institute.

[41]  C. Collins,et al.  Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. , 1994, British journal of urology.

[42]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[43]  J. Moul,et al.  Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. , 1993, The Journal of urology.

[44]  R. Sadasivan,et al.  Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. , 1993, The Journal of urology.

[45]  D. Giri,et al.  Expression of NEU/HER‐2 oncoprotein (p185neu) in prostate tumors: An immunohistochemical study , 1993, The Prostate.

[46]  T. Visakorpi,et al.  Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[47]  W. Isaacs,et al.  Androgen receptor gene mutations in human prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[48]  D. Gleason,et al.  Histologic grading of prostate cancer: a perspective. , 1992, Human pathology.

[49]  G. Jenster,et al.  The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens , 1992, Journal of Steroid Biochemistry and Molecular Biology.

[50]  T. H. van der Kwast,et al.  Androgen receptors in endocrine‐therapy‐resistant human prostate cancer , 1991, International journal of cancer.

[51]  S. Naber,et al.  Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma. , 1990, American journal of clinical pathology.

[52]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[53]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[54]  N. Kyprianou,et al.  Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration , 1989, The Prostate.

[55]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[56]  A A Tsiatis,et al.  Exact significance testing to establish treatment equivalence with ordered categorical data. , 1984, Biometrics.

[57]  D. Siegmund,et al.  Maximally Selected Chi Square Statistics , 1982 .

[58]  D. Cox,et al.  The analysis of binary data , 1971 .

[59]  A. R. Jonckheere,et al.  A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES , 1954 .

[60]  F. Wilcoxon.  Individual Comparisons by Ranking Methods , 1945 .